Moorthy Palanki

🚀 Revolutionizing Molecular Diagnostics in Underserved Regions with Reme-D.Inc 🌍 Discover how Reme-D.Inc., led by Dr. Salma Tammam, is revolutionizing molecular diagnostics in underserved regions by focusing on affordable and accessible healthcare solutions for the Middle East and Africa. 🔬 Inspiration and Innovation: Dr. Salma's journey from academia to founding Reme-D was sparked by the COVID-19 pandemic, highlighting the urgent need for region-specific, cost-effective diagnostic solutions. 🌟 Mission-Driven Approach: Reme-D focuses on creating room temperature-stable tests with simplified protocols, overcoming high costs and complex procedures. 👩‍🔬 Empowering Female Entrepreneurs: Dr. Salma champions support for female founders in Egypt, contributing to the rise of tech and biotech startups. 🌟 Egypt's Tech Hub: With the rise of startups like MNT-Halan, Egypt is emerging as a key regional tech player, driven by resilience and robust support systems like Creativa. 💡 Vaccine Apartheid and Self-Sufficiency: Dr. Salma advocates for Africa's self-reliance in vaccine production and pharmaceuticals to address "vaccine apartheid" and build a sustainable healthcare ecosystem. 🔗 Building Trust and Collaboration: Emphasizing the need for credibility in local products and a collaborative platform to foster innovation across Africa. 🌟 Advice for Entrepreneurs: Stay resilient, believe in your vision, and make a difference despite the challenges. for full EP: https://lnkd.in/eXxfwSD4 #Innovation #Healthcare #Diagnostics #Entrepreneurship #Tech #Africa #MiddleEast #Biotech #Sustainability

4

https://lnkd.in/gUfz_DYt Native mass spec can be an excellent orthogonal validation technique to NMR for fragment campaigns.

2

The LIMR Chemical Genomics Center (LCGC) provides unique resources for scientists worldwide to improve drug discovery efficiency by 500%. LCGC's patented infrastructure enables innovative public-private partnering initiatives to identify novel combination-drug synergies. Watch to learn more: https://bit.ly/3PJBdxI

9

1 Comment

Catch a recap of a recent #ISCT2024 roundtable in #Vancouver moderated by Dalip Sethi, PhD, MBA - "Current State and Future Directions of #ProcessAnalyticalTechnologies in the CGT Space." #CellGeneTherapies #CellTherapy #GeneTherapy #PAT ISCT, International Society for Cell & Gene Therapy

89

2 Comments

Join BenevolentAI and Rancho Biosciences for an informative discussion to learn how single-cell transcriptomics data at scale is helping to revolutionize drug discovery by providing deeper insights into cellular mechanisms. https://lnkd.in/gZt7PjrN In these presentations we will discuss:  - The importance of high-quality data to produce meaningful insights and the robust workflows created to deliver analysis-ready single-cell transcriptomics datasets at scale  - Introduction to BenevolentAI’s target discovery platform as illustrated by several cases studies that demonstrate its utility for mechanistic drug discovery.  - How to prepare volumes of high-quality data for meaningful insights Learn how these innovative, AI-driven, disease agnostic approaches can transform your research, and lead to more effective, novel drug discovery outcomes more rapidly. #DrugDiscovery #SingleCellTranscriptomics #AIinHealthcare #Biotechnology #DataScience #PrecisionMedicine #ResearchInnovation #CellularMechanisms #BenevolentAI #RanchoBiosciences #HighQualityData #MechanisticInsights #PharmaceuticalResearch #HealthcareInnovation

34

HEK293 Cells through Glycopeptide Mapping and Released Glycan Analysis Recombinant adeno-associated viral (AAV) vectors have emerged as prominent gene delivery vehicles for gene therapy. AAV capsid proteins determine tissue specificity and immunogenicity and play important roles in receptor binding, the escape of the virus from the endosome, and the transport of the viral DNA to the nuclei of target cells. Therefore, the comprehensive characterization of AAV capsid proteins is necessary for a better understanding of the vector assembly, stability, and transduction efficiency of AAV gene therapies. Glycosylation is one of the most common post-translational modifications (PTMs) and may affect the tissue tropism of AAV gene therapy. However, there are few studies on the characterization of the N- and O-glycosylation of AAV capsid proteins. In this study, we identified the N- and O-glycosylation sites and forms of AAV9 capsid proteins generated from HEK293 cells using liquid chromatography–tandem mass spectrometry (LC-MS)-based glycopeptide mapping and identified free N-glycans released from AAV9 capsid proteins by PNGase F using hydrophilic interaction. https://lnkd.in/e6z6TKHz

89

"AI for drug discovery can hit at all the inefficiencies in every step of the drug design process." - Surya Ganguli, a16z venture partner and Professor at Stanford University. Recently, Surya and Bowen Liu, a16z investment partner, joined Vijay Pande, PhD to go deep on AI in Bio. The trio dove into many aspects of AI in life sciences including the potential applications of self-supervised learning, which allows AI to learn from vast amounts of unlabelled data, drastically improving the prediction and design of new drugs. Listen on Raising Health: https://lnkd.in/dzjQ3Bux

44

3 Comments

In recent years, the potential of mRNA therapies has been well demonstrated. However, the development of nucleic acid drugs faces numerous challenges, including reducing immunogenicity, improving stability, enhancing in vivo delivery efficiency, and achieving appropriate biodistribution. To address these challenges, WuXi Biology has established a preclinical pharmacology platform to specifically support the research and development of mRNA and other nucleic acid drugs. In our latest issue of OncoWuXi Express, we showcase how the WuXi Biology team designed and synthesized an mRNA sequence encoding Interleukin-12 (IL-12) and encapsulated it in lipid nanoparticles to prepare IL-12 mRNA LNPs for assessing antitumor efficacy. Click this link 👇 to read our article: https://lnkd.in/gHB9QbuW #Biotech #DrugDiscovery #mRNA #NucleicAcids #Oligonucleotides

9

A collaborative study involving Scripps Research has uncovered a critical vulnerability in Plasmodium falciparum, the parasite responsible for severe malaria. Researchers identified how broadly neutralizing antibodies (bnAbs) block a key site on the PfEMP1 protein, which is essential for the parasite’s survival in its host. This site, which cannot mutate without jeopardizing the parasite’s ability to infect, is a promising target for next-generation malaria vaccines. “Importantly, this study reveals how immunity can arise despite the parasite’s use of a highly mutated antigen to infect its host—a puzzle that has baffled scientists for many years,” says co-first author Sai Sundar Rajan Raghavan, PhD, from the Ward Lab at Scripps Research. Published in Nature Magazine, the study was conducted with collaborators from leading institutions, including the Københavns Universitet - University of Copenhagen; the UT Health San Antonio; the Fred Hutch Cancer Research Center in Seattle, EMBL Barcelona; the University of California, San Francisco; the Tanga Research Centre in Tanzania; and the Infectious Disease Research Centre in Uganda. Learn more at: https://ow.ly/MitX50Ue371

161

LABN Trending News: Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies https://lnkd.in/g3RAWEQm FOSTER CITY, Calif. & LOS ANGELES–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across [...]

1

ASCO2024 Updates: Soki Kashima on Single-Cell RNA Sequencing in RCC American Society of Clinical Oncology (ASCO) https://lnkd.in/eizJX3Jk #ASCO #ASCO24 #ASCO24Updates #Cancer #OncoDaily #OncoDailyASCO24Updates #Oncology #Medicine #Health

21

SFBN Feed: 23andMe and Mirador Therapeutics Enter Into Strategic Research Collaboration to Advance Mirador’s Precision Medicines for Immunology & Inflammation https://lnkd.in/g6ybViDC SUNNYVALE, Calif. and SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) — 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and preventive health company, and Mirador Therapeutics, a next-generation precision medicine company focused on developing [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

2

From MBoC The CCT chaperonin and actin modulate the ER and RNA-binding protein condensation during oogenesis and maintain translational repression of maternal mRNA and oocyte quality The mechanisms regulating phase transitions of oogenic RNA-binding proteins are critical for oocyte quality. Schisa et. al identify the CCT chaperonin and actin as novel regulators of ER structure, RNA-binding protein phase transitions, and translational regulation in C. elegans oocytes. https://lnkd.in/eSAgmfa8

3

The University of Southern California announces strategic collaboration with Autobahn Labs, Inc. to accelerate drug discovery. The Stevens Center will closely work with MESH Strategic Partnerships, Keck School of Medicine of USC on this new effort, and we'll aim to rapidly transform academic breakthroughs into life-saving therapies for a range of medical conditions. “Our collaboration with Autobahn Labs is a pivotal moment for our institution’s mission to bring academic innovations in drug discovery to market,” said Erin Overstreet PhD, executive director of the USC Stevens Center for Innovation, which manages a broad portfolio of university-owned intellectual property. “By leveraging USC’s scientific expertise and Autobahn’s drug discovery capabilities, we are accelerating the development of novel therapeutics that address critical medical needs and improve patient outcomes,” she said. Read more about this exciting collaboration: https://lnkd.in/gqNSWK8w

7

1 Comment

UC San Diego HUMANOID: Center of Excellence in Human Organoid Research just released its updated website (👇). Our #biobank operates under a expansive IRB that covers all #organs, #diseases, and ages ranging from the #cradle to the #grave. But what we do best is #benchmarking #organoids for their use in Phase '0' #human trials (#drugdiscovery, #genetherapy, #target and #biomarker validation, #foundational research into cell #state, #shape and #fate). Let us know how we can help you in your #organoid (and primary cell-based) #research. Link to website: https://lnkd.in/gCPurB_P Link to services & recharge: https://lnkd.in/gXfMrHkC Contact Us: Courtney Tindle [[email protected]]

69

#Autoimmunity | #Sex, #Cells & #Metabolism: #Androgens temper #Th17-driven #Immunity | Nikita Mani & Sam Weinberg give expert commentary* on new Dawn Newcomb & Co. study at The Journal of Clinical Investigation | Sex-based differences in autoimmune disease susceptibility have long been recognized, prompting investigations into how sex hormones influence immunity. Recent advances suggest that hormones may shape immune responses by altering cellular metabolism. In the latest issue of the JCI** Nowrin Chowdhury, Jacqueline Cephus, Emely Henriquez Pilier, et al. authenticate this model, showing that androgen receptor signaling modulates T helper 17 (Th17) cell metabolism, specifically glutaminolysis, reducing airway inflammation in males. This work provides insight into sex-specific regulation of immunity, highlighting the interplay between hormones, metabolism, and immune function. The findings raise intriguing questions about how hormonal fluctuations affect immunity and how sex-specific metabolic pathways might be leveraged for targeted therapies in autoimmune diseases. *https://lnkd.in/egU8fHr2 **https://lnkd.in/enyWBhPw Celentyx Ltd #autoimmunediseases #drugdiscovery #CRO www.celentyx.com FIGURE | UPPER: Graphical Abstract | LOWER: Androgen receptor signaling drives differences in Th17 cell metabolism and function during allergic airway inflammation | In male Th17 cells, androgen receptor (AR) signaling suppresses glutamine metabolism, resulting in mild allergic inflammation and reduced IL-17 production. The presence of androgens activates AR, which translocates to the nucleus and potentially regulates genes involved in glutamine metabolism, though the exact mechanism of AR-mediated suppression of glutamine metabolism remains to be fully elucidated. In contrast, female Th17 cells exhibit enhanced glutamine metabolism and severe allergic inflammation. The absence of AR signaling allows for increased glutamine (GLN) uptake through plasma membrane transporters and elevated glutaminase (GLS) activity. This leads to higher glutamate (Glu) production, which feeds into the TCA cycle and contributes to glutathione (GSH) synthesis. The enhanced glutamine metabolism in female Th17 cells correlates with increased IL-17 production and secretion, exacerbating allergic inflammation. Further research is needed to elucidate the precise molecular mechanisms linking enhanced glutamine metabolism to increased IL-17 production and Th17 cell pathogenicity in females, as the exact pathway has yet to be fully characterised |

67

4 Comments

Two recent papers -- by Fojo and Olivier -- explained why Sotorasib, a KRAS G12C inhibitor, became a regulatory setback for NSCLC? They wrote: Sotorasib was approved on the basis of a single-arm, uncontrolled phase 1–2 study (CodeBreaK 100) that reported an objective response rate (ORR) of 37% and a 11·1 month median duration of response. By contrast, other molecular therapies for NSCLC have higher ORRs; osimertinib targets EGFR-mutated NSCLC and has an ORR of 90% and alectinib targets ALK-mutated NSCLC and has reported an ORR of 82·9%.

7